Clearmind Medicine Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Clearmind Medicine Inc 公司

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.

Clearmind Medicine Inc簡介



公司代碼CMND

公司名稱Clearmind Medicine Inc

上市日期Aug 10, 2021

CEOZuloff-Shani (Adi)

員工數量- -

證券類型Ordinary Share

年結日Aug 10

公司地址101-1220 West 6Th Avenue

城市VANCOUVER

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Canada

郵編V6H 1A5

電話16042601566

網址https://www.clearmindmedicine.com/

公司代碼CMND

上市日期Aug 10, 2021

CEOZuloff-Shani (Adi)

Clearmind Medicine Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Amitay Weiss

Independent Chairman of the Board

4.62K

+3621.00%

Mr. Oz Adler, CPA

Independent Director

1.87K

+1874.00%

Mr. Asaf Itzhaik

Independent Director

935.00

+935.00%

Mr. Alan Rootenberg

Chief Financial Officer

713.00

+93.00%

Dr. Adi Zuloff-Shani

Chief Executive Officer

--

Prof. Mark Haden

Vice President - Business Development

--

-3.00%

Mr. Yehonatan Shachar

Independent Director

--

Ms. Hila Kiron-Revach

Director

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Amitay Weiss

Independent Chairman of the Board

4.62K

+3621.00%

Mr. Oz Adler, CPA

Independent Director

1.87K

+1874.00%

Mr. Asaf Itzhaik

Independent Director

935.00

+935.00%

Mr. Alan Rootenberg

Chief Financial Officer

713.00

+93.00%

Dr. Adi Zuloff-Shani

Chief Executive Officer

--

Prof. Mark Haden

Vice President - Business Development

--

-3.00%

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 1月25日週日

持股股東

股東類型

持股股東

佔比

Capitalink Ltd.

9.97%

L.I.A. Pure Capital Ltd

9.97%

Daniel (Nissim)

5.51%

AdvisorShares Investments, LLC

0.37%

Shani (Adi Zuloff)

0.31%

其他

73.87%

持股股東

佔比

Capitalink Ltd.

9.97%

L.I.A. Pure Capital Ltd

9.97%

Daniel (Nissim)

5.51%

AdvisorShares Investments, LLC

0.37%

Shani (Adi Zuloff)

0.31%

其他

73.87%

股東類型

持股股東

佔比

Corporation

19.94%

Individual Investor

6.43%

Investment Advisor

0.42%

Research Firm

0.05%

其他

73.17%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

18

281.13K

2.83%

--

2025Q3

20

281.13K

17.81%

-308.29K

2025Q2

21

589.42K

18.96%

-12.36K

2025Q1

18

601.77K

18.55%

-350.88K

2024Q4

18

612.80K

20.27%

-89.61K

2024Q3

17

702.42K

8.27%

+411.62K

2024Q2

15

290.80K

5.30%

+12.32K

2024Q1

15

281.81K

3.72%

+163.87K

2023Q4

13

96.03K

1.96%

+64.13K

2023Q3

13

31.90K

2.51%

+20.39K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Capitalink Ltd.

149.51K

9.97%

+66.83K

+80.83%

Dec 03, 2025

L.I.A. Pure Capital Ltd

149.51K

9.97%

+66.83K

+80.83%

Dec 03, 2025

Daniel (Nissim)

82.68K

5.51%

+82.68K

--

Nov 19, 2025

AdvisorShares Investments, LLC

5.61K

0.37%

+461.00

+8.95%

Sep 30, 2025

Shani (Adi Zuloff)

1.36K

0.09%

+1.31K

+3128.57%

Oct 31, 2024

Weiss (Amitay)

996.00

0.07%

--

Nov 20, 2025

Shachar (Yehonatan Samuel)

312.00

0.02%

--

Nov 20, 2025

Virtu Americas LLC

714.00

0.05%

+714.00

--

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

AdvisorShares Psychedelics ETF

1.16%

Fidelity Nasdaq Composite Index ETF

0%

AdvisorShares Psychedelics ETF

佔比1.16%

Fidelity Nasdaq Composite Index ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

Dec 11, 2025

Merger

40→1

Nov 21, 2023

Merger

30→1

Nov 21, 2023

Merger

30→1

Nov 21, 2023

Merger

30→1

Nov 21, 2023

Merger

30→1

公告日期

除權除息日

類型

比率

Dec 11, 2025

Merger

40→1

Nov 21, 2023

Merger

30→1

Nov 21, 2023

Merger

30→1

Nov 21, 2023

Merger

30→1

Nov 21, 2023

Merger

30→1